Clinical Trial: ECOG-ACRIN EA2201

ECOG-ACRIN EA2201

Status: Closed

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

EA2201 is closed to accrual, effective January 14, 2025.